MARGENZA (margetuximab-cmkb)

Office Administration – Intravenous

Indications for Prior Authorization:
  • Indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease
Coverage Criteria:

For diagnosis of metastatic HER2-positive breast cancer:

  • Dose does not exceed 15 mg/kg every 3 weeks, AND
  • Patient is 18 years of age or older, AND
  • Prescribed by or in consultation with an oncologist, AND
  • Used in combination with chemotherapy (e.g., capecitabine, eribulin, gemcitabine, vinorelbine), AND
  • Failure of two anti-HER2-based regimens, at least once of which was for metastatic disease (e.g., pertuzumab + trastuzumab + docetaxel, ado-trastuzumab emtansine, etc.), unless contraindicated or clinically significant adverse effects are experienced
Reauthorization Criteria:

For diagnosis of metastatic HER2-positive breast cancer:

  • Dose does not exceed 15 mg/kg every 3 weeks, AND
  • Patient does not show evidence of progressive disease while on therapy
Coverage Duration:
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Warnings
    • Left ventricular dysfunction: Margenza may lead to reductions in left ventricular ejection fraction (LVEF).  Evaluate cardiac function prior to and during treatment
    • Embryo-fetal toxicity: exposure to Margenza during pregnancy can cause embryo-fetal harm
    • Infusion-Related Reactions (IRR’s): monitor for signs and symptoms.  If a significant infusion associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies
Policy Updates:
  • 06/15/2021 – New policy approved by P&T
References:
  • Botticelli A, Mazzuca F, Borro M, et al. FCGRs polymorphisms and response to trastuzumab in patients with HER2-positive breast cancer: Far from predictive value? World J Oncol. 2015;6(5):437-440.
  • ClinicalTrials.gov Web site. https://clinicaltrials.gov. Identifiers: NCT02689284, NCT04082364, NCT04425018. Accessed March 23, 2021.
  • Food and Drug Administration. Multi-discipline review: Margenza. 2020. FDA Web site. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000MultidisciplineR.pdf. Accessed March 23, 2021.
  • Food and Drug Administration. Press release: FDA approves margetuximab for metastatic HER2-positive breast cancer. December 17, 2020. FDA Web site. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer. Accessed March 4, 2021.
  • Margenza [package insert], Rockville, MD: MacroGenics, Inc.; December 2020.
  • Mayer IA. Systemic treatment for metastatic breast cancer: general principles. UpToDate Web site. Updated November 11, 2020. www.uptodate.com. Accessed March 23, 2021.
  • National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology – Breast cancer, version 3.2021 – March 29, 2021. NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April 7, 2021.
  • Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
  • Rugo HS, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A Phase 3 randomized clinical trial. Epub ahead of print. JAMA Oncol. 2021 Jan 22:e207932. doi: 10.1001/jamaoncol.2020.7932.
  • Schott AF. Systemic treatment for HER2-positive metastatic breast cancer. UpToDate Web site. Updated January 19, 2021. www.uptodate.com. Accessed March 23, 2021.
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33

 

 

Last review date: June 15, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone